/ESPR
ESPR Stock - Esperion Therapeutics, Inc.
Healthcare|Drug Manufacturers - Specialty & GenericNASDAQ
$3.93+3.42%
+$0.13 (+3.42%) • Dec 19
86
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.100
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.80
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+129.0%upside
Target: $9.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ESPR
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$3.89 – $3.97
TARGET (TP)$9.00
STOP LOSS$3.62
RISK/REWARD1:16.4
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.01
52W High$4.13
52W Low$0.69
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $332.31M | $116.33M | $75.47M | $78.45M | $227.55M |
| Gross Profit | $263.71M | $73.07M | $48.51M | $64.23M | $225.16M |
| Gross Margin | 79.4% | 62.8% | 64.3% | 81.9% | 98.9% |
| Operating Income | $54.40M | $-155,563,000 | $-179,501,000 | $-226,730,000 | $-121,396,000 |
| Net Income | $-51,745,000 | $-209,248,000 | $-233,659,000 | $-269,108,000 | $-143,551,000 |
| Net Margin | -15.6% | -179.9% | -309.6% | -343.0% | -63.1% |
| EPS | $-0.28 | $-2.03 | $-4.33 | $-11.03 | $-6.05 |
Company Overview
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
2
17%
Hold / Neutral
7
58%
Sell / Underperform
3
25%
Analyst Consensus🔴 Bearish
2 Bullish10 Neutral/Bearish
Price Targets
$6
Average Target
↑ 52.7% Upside
Now
$1
Low
$6
Average
$12
High
Based on 13 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 25th 2025 | Piper Sandler | Initiation | Overweight | $9 |
| December 18th 2024 | Goldman | Initiation | Neutral | $4 |
| December 17th 2024 | Cantor Fitzgerald | Initiation | Overweight | $8 |
| June 20th 2024 | BofA Securities | Downgrade | Underperform | $2.5 |
| January 3rd 2024 | BofA Securities | Downgrade | Neutral | - |
| November 20th 2023 | JP Morgan | Resumed | Neutral | - |
| August 1st 2023 | Northland Capital | Upgrade | Market Perform | - |
| June 15th 2023 | BofA Securities | Upgrade | Buy | $4← $1.25 |
| March 16th 2023 | Northland Capital | Downgrade | Under Perform | $1 |
| March 16th 2023 | BofA Securities | Downgrade | Underperform | $1.5← $8 |
| March 7th 2023 | Credit Suisse | Upgrade | Neutral | $7← $6.5 |
| February 27th 2023 | BofA Securities | Resumed | Neutral | $8 |
| February 24th 2023 | Jefferies | Upgrade | Buy | $12 |
| February 3rd 2023 | Morgan Stanley | Upgrade | Equal Weight | $9 |
| August 3rd 2022 | Credit Suisse | Downgrade | Underperform | $6← $7 |
Earnings History & Surprises
ESPRBeat Rate
72%
Last 18 quarters
Avg Surprise
+41.3%
EPS vs Estimate
Beats / Misses
13/5
Last 12 quarters
Latest EPS
$-0.16
Q4 2025
EPS Surprise History
Q1 24
+5.7%
$-0.50vs$-0.53
Q2 24
+580.0%
$0.34vs$0.05
Q3 24
+66.7%
$-0.05vs$-0.15
Q4 24
-7.1%
$-0.15vs$-0.14
Q1 25
+28.6%
$-0.10vs$-0.14
Q2 25
-16.7%
$-0.21vs$-0.18
Q3 25
+88.2%
$-0.02vs$-0.17
Q4 25
-77.8%
$-0.16vs$-0.09
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 4, 2026 | — | — | — | — |
Q1 2026 | Mar 3, 2026 | $0.15 | — | — | — |
Q4 2025 | Nov 6, 2025 | $-0.09 | $-0.16 | -77.8% | ✗ MISS |
Q3 2025 | Aug 5, 2025 | $-0.17 | $-0.02 | +88.2% | ✓ BEAT |
Q2 2025 | May 6, 2025 | $-0.18 | $-0.21 | -16.7% | ✗ MISS |
Q1 2025 | Mar 4, 2025 | $-0.14 | $-0.10 | +28.6% | ✓ BEAT |
Q4 2024 | Nov 7, 2024 | $-0.14 | $-0.15 | -7.1% | ✗ MISS |
Q3 2024 | Aug 12, 2024 | $-0.15 | $-0.05 | +66.7% | ✓ BEAT |
Q2 2024 | May 7, 2024 | $0.05 | $0.34 | +580.0% | ✓ BEAT |
Q1 2024 | Feb 27, 2024 | $-0.53 | $-0.50 | +5.7% | ✓ BEAT |
Q4 2023 | Nov 7, 2023 | $-0.42 | $-0.37 | +11.9% | ✓ BEAT |
Q3 2023 | Aug 1, 2023 | $-0.63 | $-0.46 | +27.0% | ✓ BEAT |
Q2 2023 | May 9, 2023 | $-0.65 | $-0.79 | -21.5% | ✗ MISS |
Q1 2023 | Feb 21, 2023 | $-0.87 | $-0.76 | +12.6% | ✓ BEAT |
Q4 2022 | Nov 1, 2022 | $-0.93 | $-0.81 | +12.9% | ✓ BEAT |
Q3 2022 | Aug 2, 2022 | $-0.95 | $-1.05 | -10.5% | ✗ MISS |
Q2 2022 | May 3, 2022 | $-0.96 | $-0.93 | +3.1% | ✓ BEAT |
Q1 2022 | Feb 22, 2022 | $-2.32 | $-1.77 | +23.7% | ✓ BEAT |
Q4 2021 | Nov 2, 2021 | $-2.86 | $-2.62 | +8.4% | ✓ BEAT |
Q3 2021 | Aug 3, 2021 | $-1.82 | $-1.67 | +8.2% | ✓ BEAT |
Latest News
Esperion's Bempedoic Acid Receives Recommendation iI 2025 ACC Scientific Statement On Management Of Peripheral Artery Disease In Adults With Diabetes
📈 PositiveBenzinga•Dec 19, 2025, 01:04 PM
Esperion a new overweight at Piper Sandler on CV franchise
📈 PositiveSeeking Alpha•Nov 25, 2025, 05:42 PM
Esperion Therapeutics shares are trading higher after Piper Sandler initiated coverage on the stock with an Overweight rating and a $9 price target.
📈 PositiveBenzinga•Nov 25, 2025, 04:59 PM•Also:
Piper Sandler Initiates Coverage On Esperion Therapeutics with Overweight Rating, Announces Price Target of $9
📈 PositiveBenzinga•Nov 25, 2025, 02:19 PM
Esperion's Japan Partner Otsuka Pharmaceutical Gets National Health Insurance Price Listing To Roll Out NEXLETOL For Hypercholesterolemia, Familial Hypercholesterolemia Treatment
📈 PositiveBenzinga•Nov 21, 2025, 01:01 PM
Esperion Partner, HLS Therapeutics, Receives Health Canada Approval To Market NILEMDO For Reduction Of LDL-Cholesterol
📈 PositiveBenzinga•Nov 18, 2025, 12:08 PM•Also:
Esperion Presents Two Post Hoc Analyses From CLEAR Outcomes Focused On MACE And VTE, At AHA Scientific Sessions 2025
➖ NeutralBenzinga•Nov 10, 2025, 01:08 PM
Esperion Therapeutics shares are trading lower after the company reported worse-than-expected Q3 EPS results.
📉 NegativeBenzinga•Nov 6, 2025, 04:57 PM
Esperion Therapeutics Q3 EPS $(0.16) Misses $(0.08) Estimate, Sales $87.309M Beat $77.803M Estimate
➖ NeutralBenzinga•Nov 6, 2025, 11:01 AM
Esperion To Present New CLEAR Outcomes Data On Bempedoic Acid At AHA 2025 Scientific Sessions
➖ NeutralBenzinga•Oct 27, 2025, 12:02 PM
Esperion Nominates ESP-2001 As Preclinical Development Candidate For Primary Sclerosing Cholangitis
📈 PositiveBenzinga•Oct 16, 2025, 12:05 PM
Esperion Therapeutics shares are trading lower after the company announced the pricing of its $75 million offering of 30 million shares at $2.50 per share.
📉 NegativeBenzinga•Oct 8, 2025, 12:56 PM
Reported Earlier, Esperion Therapeutics Prices 30M Common Share Offering At $2.50 Per Share For Gross Proceeds Of $75M
➖ NeutralBenzinga•Oct 8, 2025, 06:55 AM
Esperion slides after pricing $75M stock offering
📉 NegativeSeeking Alpha•Oct 8, 2025, 05:24 AM
Esperion Therapeutics shares are trading lower after the company announced a public offering of common stock.
📉 NegativeBenzinga•Oct 7, 2025, 08:16 PM
Esperion launches proposed public offering of common stock; shares fall 21%
📉 NegativeSeeking Alpha•Oct 7, 2025, 08:15 PM
Esperion Announces Proposed Public Offering Of Common Stock; Terms Not Disclosed
➖ NeutralBenzinga•Oct 7, 2025, 08:03 PM
Esperion Therapeutics Shares Halted On Circuit Breaker To The Downside, Stock Now Up 16.03%
➖ NeutralBenzinga•Oct 3, 2025, 01:58 PM
Esperion, Dr. Reddy's Laboratories Reach Patent Dispute Settlement; Dr. Reddy's Agrees Not To Market NEXLETOL Or NEXLIZET In US Before 2040
📈 PositiveBenzinga•Oct 3, 2025, 12:04 PM•Also:
HC Wainwright & Co. Reiterates Buy on Esperion Therapeutics, Maintains $16 Price Target
📈 PositiveBenzinga•Sep 19, 2025, 01:23 PM
Frequently Asked Questions about ESPR
What is ESPR's current stock price?
Esperion Therapeutics, Inc. (ESPR) is currently trading at $3.93 per share. The stock has moved +3.42% today.
What is the analyst price target for ESPR?
The average analyst price target for ESPR is $9.00, based on 1 analyst.
What sector is Esperion Therapeutics, Inc. in?
Esperion Therapeutics, Inc. operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. The company is traded on the NASDAQ exchange.
What is ESPR's market cap?
Esperion Therapeutics, Inc. has a market capitalization of $0.78 billion, making it a small-cap company.
Does ESPR pay dividends?
No, Esperion Therapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorABSI
Absci Corporation
$3.38
Mkt Cap: $0.5B
AQST
Aquestive Therapeutics, Inc.
$5.80
Mkt Cap: $0.6B
CRVS
Corvus Pharmaceuticals, Inc.
$7.49
Mkt Cap: $0.6B
EBS
Emergent BioSolutions Inc.
$12.42
Mkt Cap: $0.7B
OFIX
Orthofix Medical Inc.
$15.46
Mkt Cap: $0.6B
OLMA
Olema Pharmaceuticals, Inc.
$27.93
Mkt Cap: $1.9B
RGNX
REGENXBIO Inc.
$14.59
Mkt Cap: $0.7B
SIGA
SIGA Technologies, Inc.
$6.27
Mkt Cap: $0.4B
SNDL
SNDL Inc.
$1.92
Mkt Cap: $0.5B
VTYX
Ventyx Biosciences, Inc.
$8.74
Mkt Cap: $0.6B
Explore stocks similar to ESPR for comparison